BIOSMELT PHARMA

BIOSMELT PHARMA was established in 2021 as a CRO company focused on the development of novel delivery technologies and cell and gene therapy drugs. It primarily serves biotech innovators by providing preclinical process development, methodology development, GMP-level pilot and intermediate-scale production, and IND registration services. In 2022, BIOSMELT PHARMA completed the construction of a 1500m² GMP laboratory, successfully obtained third-party GMP certification, and secured the BSL-2 lab accreditation for pathogenic microorganisms. The company filed six utility model patent applications. Meanwhile, its subsidiary, Tuling Bio (MedMerck), was recognized as a high-precision specialty enterprise in Minhang District, and BIOSMELT PHARMA signed its first innovative drug IND application service contract, which is currently ongoing.